Mylan board gets re-elected despite EpiPen scandal

Mylan shareholders re-elected the generic drugmaker's board at its annual meeting on Thursday, despite a shareholder campaign to vote down most of the directors in the wake of a scandal related to its high prices for emergency allergy treatment EpiPen. The company did not disclose the vote totals for the directors. More than two-thirds of...